"We believe that our therapeutic approach to the treatment of Huntington's disease has provided a biological rationale linking Huntington's disease progression and toxic N-terminal fragments. We look forward to completing our plans for human patient trials," says Lee Henderson, PhD, CEO of Vybion.
About Vybion: Vybion, Inc. is a development stage Company with proprietary technologies for Intrabody discovery and development to treat neurodegenerative diseases such as Huntington's, SBMA and SCA1, 3 and 7. The Company is currently in late pre-clinical development with INT41 in Huntington's Disease. The Intrabody platform is applicable to target validation in intracellular signal transduction pathways and can be applied to multiple therapeutic areas.
About Inverness: Inverness Advisors LLC, based in San Francisco and a division of KEMA Partners LLC, is an investment bank that provides capital raising and mergers & acquisitions advisory services to clients in the technology, media and healthcare industries. Inverness Advisors conducts all securities business through KEMA Partners LLC, a FINRA member and SEC-registered broker-dealer.
Lee A. Henderson, Ph.D.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/novel-gene-therapy-drug-for-huntingtons-disease-300317166.html
SOURCE Vybion, Inc.